OBJECTIVE: The purpose of this study was to evaluate vascular endothelial growth factor (VEGF) expression in adenocarcinomas of the uterine cervix and its correlation with clinicopathologic features, angiogenesis, and expression of p53 and c-erbB-2 proteins. METHODS: Thirty-seven cases of FIGO clinical stage I and II adenocarcinoma of the uterine cervix were examined by immunohistochemical studies with anti-VEGF, anti-CD34, anti-p53, and anti-c-erbB-2 antibodies. Computerized image analysis was used to evaluate microvessel density (MVD). RESULTS: Thirty-one tumors (83.8%) were classified as VEGF positive. Six tumors (16.2%) showed p53 protein expression while 11 tumors (29.7%) expressed the c-erbB-2 protein. MVD ranged from 13.3 to 44.8, with a median value of 25.5 (26.9 +/- 7.5). Tumors expressing VEGF had a significantly higher MVD than those that did not express VEGF (P < 0.05). VEGF expression was significantly associated with c-erbB-2 protein expression (P < 0.05). The spatial distributions of both VEGF expression and c-erbB-2 expression were similar in tumor tissues. In univariate log-rank analysis, stage (P = 0.0250), lymphovascular space invasion (P = 0.0156), and MVD (P = 0.0360) were associated with shortened survival. CONCLUSION: VEGF expression plays a role in promoting angiogenesis in cervical adenocarcinomas and c-erbB-2 is likely to be involved in the up-regulation of VEGF expression.
OBJECTIVE: The purpose of this study was to evaluate vascular endothelial growth factor (VEGF) expression in adenocarcinomas of the uterine cervix and its correlation with clinicopathologic features, angiogenesis, and expression of p53 and c-erbB-2 proteins. METHODS: Thirty-seven cases of FIGO clinical stage I and II adenocarcinoma of the uterine cervix were examined by immunohistochemical studies with anti-VEGF, anti-CD34, anti-p53, and anti-c-erbB-2 antibodies. Computerized image analysis was used to evaluate microvessel density (MVD). RESULTS: Thirty-one tumors (83.8%) were classified as VEGF positive. Six tumors (16.2%) showed p53 protein expression while 11 tumors (29.7%) expressed the c-erbB-2 protein. MVD ranged from 13.3 to 44.8, with a median value of 25.5 (26.9 +/- 7.5). Tumors expressing VEGF had a significantly higher MVD than those that did not express VEGF (P < 0.05). VEGF expression was significantly associated with c-erbB-2 protein expression (P < 0.05). The spatial distributions of both VEGF expression and c-erbB-2 expression were similar in tumor tissues. In univariate log-rank analysis, stage (P = 0.0250), lymphovascular space invasion (P = 0.0156), and MVD (P = 0.0360) were associated with shortened survival. CONCLUSION:VEGF expression plays a role in promoting angiogenesis in cervical adenocarcinomas and c-erbB-2 is likely to be involved in the up-regulation of VEGF expression.
Authors: M Branca; C Giorgi; D Santini; L Di Bonito; M Ciotti; A Benedetto; P Paba; S Costa; D Bonifacio; P Di Bonito; L Accardi; C Favalli; K Syrjänen Journal: J Clin Pathol Date: 2006-01 Impact factor: 3.411
Authors: Leslie M Randall; Bradley J Monk; Kathleen M Darcy; Chunqiao Tian; Robert A Burger; Shu-Yuan Liao; William A Peters; Richard J Stock; John P Fruehauf Journal: Gynecol Oncol Date: 2008-12-24 Impact factor: 5.482
Authors: Marta Biedka; Roman Makarewicz; Ewa Kopczyńska; Andrzej Marszałek; Alina Goralewska; Hanna Kardymowicz Journal: Contemp Oncol (Pozn) Date: 2012-02-29
Authors: K Matsuo; S Mabuchi; M Okazawa; Y Matsumoto; T Tsutsui; M Fujita; S Kamiura; K Ogawa; C P Morrow; T Kimura Journal: Br J Cancer Date: 2013-03-05 Impact factor: 7.640
Authors: Koji Matsuo; Todd B Sheridan; Kiyoshi Yoshino; Takahito Miyake; Karina E Hew; Dwight D Im; Neil B Rosenshein; Seiji Mabuchi; Takayuki Enomoto; Tadashi Kimura; Anil K Sood; Lynda D Roman Journal: Cancer Med Date: 2012-09-14 Impact factor: 4.452